Homology Medicines, Inc. (FIXX) [Rocket]

Overview

Homology Medicines, Inc. (FIXX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/10/2023	8-K	Quarterly results
08/14/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/07/2023	4	Jordan Julie (Chief Medical Officer) has filed a Form 4 on Homology Medicines, Inc.
08/04/2023	4	Jordan Julie (Chief Medical Officer) has filed a Form 4 on Homology Medicines, Inc.
07/27/2023	8-K	Cost Associated with Exit or Disposal Activities, Other Events  Interactive Data
06/15/2023	4	GILLIS STEVEN (Director) has filed a Form 4 on Homology Medicines, Inc.
06/15/2023	4	Patterson Matthew R (Director) has filed a Form 4 on Homology Medicines, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
Revenues	3.2	34.0	2.7	1.7	5.3	0.0	5,695.0
Revenue growth	-90.6%	1157.3%	62.2%	-68.7%		-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	10,000.0
Gross profit	3.2	34.0	2.7	1.7	5.3	0.0	-4,305.0
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%		-75.6%
Selling, general and administrative	136.5	129.9	133.0
Research and development				89.4	47.9	21.4
General and administrative				22.2	17.3	8.3	4,305.0
EBIT	-2.0	-95.9	-130.3	-109.9	-59.9	-29.7	-10,000.0
EBIT margin	-63.3%	-282.4%	-4821.0%	-6599.2%	-1126.0%		-175.6%
Pre-tax income	1.2	-95.8	-128.7	-103.9	-55.6	-30.0	0.0
Income taxes	0.7	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	59.7%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-5.0	-95.8	-128.7	-103.9	-55.6	-30.0	0.0
Net margin	-156.0%	-281.9%	-4762.9%	-6237.5%	-1044.3%		0.0%

Diluted EPS	($0.09)	($1.73)	($2.80)	($2.47)	($1.95)	($12.10)	$0.00
Shares outstanding (diluted)	57.4	55.3	45.9	42.1	28.6	2.5	1,900.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.